Status:
COMPLETED
Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Gilead Sciences
Conditions:
Colonic Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test the safety of the peptide and antibody and at the same time evaluate the tumor imaging of a two step antibody technique in nuclear imaging.
Detailed Description
Colo-rectal cancer has an incidence of 8000 cases per year in The Netherlands. Eventually 50% of them will die as a consequence of this disease. Treatment consists of resection of the primary tumor, ...
Eligibility Criteria
Inclusion
- \> 18 years of age
- Histologic or cytologic diagnosis of colorectal cancer
- Karnofsky performance status \>70%
Exclusion
- Pregnant or lactating women
- Severe anorexia
- Active second primary malignancy
- Chemotherapy or radiotherapy within four weeks of study entry
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00185081
Start Date
July 1 2005
End Date
December 1 2008
Last Update
April 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Centre Nijmegen
Nijmegen, Gelderland, Netherlands, 6500 HB